Imatinib-associated hyperpigmentation, a side effect that should be recognized

被引：40

作者：

Mcpherson, T. ^{[1
]}

Sherman, V. ^{[1
]}

Turner, R. ^{[1
]}

机构：

[1] Churchill Hosp, Oxford OX3 7LJ, England

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2009年 / 23卷 / 01期

关键词：

CHRONIC MYELOID-LEUKEMIA; MESYLATE; INHIBITORS; TOXICITY; THERAPY; SKIN;

D O I：

10.1111/j.1468-3083.2008.02706.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：83 / 83

页数：1

共 9 条

[1] Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate [J].

Arora, B ;

Kumar, L ;

Sharma, A ;

Wadhwa, J ;

Kochupillai, V .

ANNALS OF ONCOLOGY, 2004, 15 (02) :358-359

[2] Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia [J].

Deguchi, N. ;

Kawamura, T. ;

Shimizu, A. ;

Kitamura, R. ;

Yanagi, M. ;

Shibagaki, N. ;

Matsue, H. ;

Shimada, S. . .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (06) :1216-1218

[3] Nail toxicity associated with epidermal growth factor receptor inhibitor therapy [J].

Fox, Lindy P. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (03) :460-465

[4] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[5]

Prabhash K, 2006, Indian J Dermatol Venereol Leprol, V72, P63

[6] Cutaneous side-effects of kinase inhibitors and blocking antibodies [J].

Robert, C ;

Soria, JC ;

Spatz, A ;

Le Cesne, A ;

Malka, D ;

Pautier, P ;

Wechsler, J ;

Lhomme, C ;

Escudier, B ;

Boige, V ;

Armand, JP ;

Le Chevalier, T .

LANCET ONCOLOGY, 2005, 6 (07) :491-500

[7] Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors [J].

Segaert, S ;

Van Cutsem, E .

ANNALS OF ONCOLOGY, 2005, 16 (09) :1425-1433

[8] Imatinib mesylate causes hypopigmentation in the skin [J].

Tsao, AS ;

Kantarjian, H ;

Cortes, J ;

O'Brien, S ;

Talpaz, M .

CANCER, 2003, 98 (11) :2483-2487

[9] Adverse cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients [J].

Valeyrie, L ;

Bastuji-Garin, S ;

Revuz, J ;

Bachot, N ;

Wechsler, J ;

Berthaud, P ;

Tulliez, M ;

Giraudier, S .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (02) :201-206

← 1 →